State Street
CGTX icon

State Street’s Cognition Therapeutics CGTX Stock Holding History

State Street’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Buy
348,983
+34,500
+11% +$40.8K ﹤0.01% 3646
2026
Q1 		$239K Hold
314,483
– – ﹤0.01% 3845
2025
Q4 		$425K Sell
314,483
-10,500
-3% -$17K ﹤0.01% 3722
2025
Q3 		$439K Buy
324,983
+203,133
+167% +$277K ﹤0.01% 3691
2025
Q2 		$37.7K Hold
121,850
– – ﹤0.01% 4132
2025
Q1 		$51.3K Hold
121,850
– – ﹤0.01% 4092
2024
Q4 		$85.5K Buy
121,850
+59,100
+94% +$29.2K ﹤0.01% 4021
2024
Q3 		$29.4K Hold
62,750
– – ﹤0.01% 4179
2024
Q2 		$104K Buy
62,750
+12,000
+24% +$23.9K ﹤0.01% 4003
2024
Q1 		$92.4K Hold
50,750
– – ﹤0.01% 4043
2023
Q4 		$93.9K Hold
50,750
– – ﹤0.01% 4067
2023
Q3 		$73.1K Buy
50,750
+20,500
+68% +$32.1K ﹤0.01% 4190
2023
Q2 		$55.4K Hold
30,250
– – ﹤0.01% 4394
2023
Q1 		$59.9K Hold
30,250
– – ﹤0.01% 4462
2022
Q4 		$63.5K Buy
30,250
+15,600
+106% +$31.5K ﹤0.01% 4497
2022
Q3 		$28K Buy
+14,650
New +$30.5K ﹤0.01% 4777

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

State Street's CGTX Position: Q2 2026 in Review

State Street increased its Cognition Therapeutics (CGTX) stake by 11% in Q2 2026, buying an estimated $40.8K and bringing the position to 348,983 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #3646.

State Street first reported a position in CGTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $439K in Q3 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • State Street held 348,983 shares of Cognition Therapeutics worth $401K as of Q2 2026.
  • State Street bought 34,500 Cognition Therapeutics shares in Q2 2026, an estimated $40.8K.
  • Cognition Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3646 holding.
  • State Street first reported a position in Cognition Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • State Street's Cognition Therapeutics position peaked at $439K in Q3 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.